Glenmark Pharmaceuticals has promoted Gopal J Rawal to Senior Vice President – Sales & Marketing, marking a significant leadership move as the company accelerates its innovation-led growth across specialty and oncology portfolios in India.
In his new role, Rawal will lead the national commercial strategy, focusing on market expansion, access programmes and portfolio growth across oncology, critical care and novel therapy platforms. The elevation underscores Glenmark’s emphasis on strengthening its presence in high-impact therapeutic areas and improving patient access to advanced treatments.
Rawal has been associated with Glenmark Pharmaceuticals for over three years, most recently serving as Vice President – Sales & Marketing, Hospital Business Cluster. During this period, he played a pivotal role in scaling businesses across Critical Care, Oncology, Government and Corporate Institutions, contributing to wider adoption of life-saving and advanced therapies.
Under his leadership, Glenmark strengthened its oncology and specialty footprint through key launches such as Tevimbra and Brukinsa, while also laying the groundwork for upcoming therapies including Amelortinib, Trastuzumab Rezutican, and the long-term innovation platform ISB 2001.
An experienced commercial leader, Rawal brings a strong background in pharmaceutics, oncology, hematology and hospital sales. He holds an MBA in Marketing from M.P. Birla Institute of Management Studies and has a demonstrated track record of driving growth and operational excellence in the pharmaceutical industry.